INS and type 1 diabetes mellitus: Trial sequential analysis showed that all meta-analyses of primary outcomes were underpowered.<h4>Conclusions</h4>Current research shows no differential effects between regular human insulins and rapid-acting insulin analogues for children and adolescents with type 1 diabetes, but the evidence is very uncertain.<h4>Prospero registration number</h4>CRD42024508625.